Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

15-01-2018 | Prader-Willi syndrome | Case report | Article

Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader–Willi Syndrome: A Case Report

Journal: Diabetes Therapy

Authors: Yukio Horikawa, Mayumi Enya, Makie Komagata, Ken-ichi Hashimoto, Masayo Kagami, Maki Fukami, Jun Takeda

Publisher: Springer Healthcare

Login to get access

Abstract

Introduction

Diabetes patients with Prader–Willi syndrome (PWS) are obese because of hyperphagia; weight control by dietary modification and medicine is required for glycemic control. There are several recent reports showing the effectiveness of GLP-1 receptor agonists (GLP-1RAs) for diabetes treatment in PWS.

Case Report

A 36-year-old Japanese male patient was diagnosed with PWS at 10 years of age. At age 16 years, he was diagnosed with diabetes and began to take several kinds of oral hypoglycemic agents. At age 29 years, his BMI was 39.1 kg/m2 and he was referred to our department for diabetes and obesity treatment. In the present case, the HbA1c was not improved by GLP-1RAs despite a 28-kg BW reduction, which included a 9-kg loss of muscle. Apprehensive of further loss of muscle mass, basal insulin of insulin glargine was administered in addition to GLP-1RAs. Immediately after the addition of tofogliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, the patient’s HbA1c decreased dramatically with only about an additional 3% BW reduction. We note an improvement in our case of lipid deposition in the pancreas confirmed by abdominal CT after the improvement of HbA1c. It is unknown whether this improvement of fatty pancreas was a cause or an effect of the improved glycemic control in the present case.

Conclusion

This finding clearly supports the effectiveness of combining SGLT2 inhibitors with GLP-1RAs for treatment of patients with PWS and non-alcoholic fatty pancreas disease.
Literature
1.
Seetho IW, Jones G, Thomson GA, et al. Aging in people with Prader–Willi syndrome: mortality in the UK population cohort and morbidity in an older sample of adults. Psychol Med. 2015;45:615–21.CrossRef
2.
Butler JV, Whittington JE, Holland AJ, et al. Prevalence of, and risk factors for, physical ill-health in people with Prader–Willi syndrome: a population-based study. Dev Med Child Neurol. 2002;44:248–55.CrossRefPubMed
3.
Tsuchiya T, Oto Y, Ayabe T, Obata K, Murakami N, Nagai T. Characterization of diabetes mellitus in Japanese Prader–Willi syndrome. Clin Pediatr Endocrinol. 2011;20:33–8.CrossRefPubMedPubMedCentral
4.
Sze L, Purtell L, Jenkins A, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader–Willi syndrome. J Clin Endocrinol Metab. 2011;96:E1314–9.CrossRefPubMed
5.
Seetho IW, Jones G, Thomson GA, et al. Treating diabetes mellitus in Prader–Willi syndrome with exenatide. Diabetes Res Clin Pract. 2011;92:e1–2.CrossRefPubMed
6.
Fintini D, Grugni G, Brufani C, Bocchini S, Cappa M, Crinò A. Use of GLP-1 receptor agonists in Prader–Willi syndrome: report of six cases. Diabetes Care. 2014;37:e76–7.CrossRefPubMed
7.
Busch RS, Kane MP. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgrad Med. 2017;129:686–97.CrossRefPubMed
8.
Nauck MA, Meier JJ. GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last? Lancet Diabetes Endocrinol. 2016;4:963–4.CrossRefPubMed
9.
Singh RG, Yoon HD, Wu LM, et al. Ectopic fat accumulation in the pancreas and its clinical relevance: a systematic review, meta-analysis, and meta-regression. Metabolism. 2017;69:1–13.CrossRefPubMed
10.
Kim SY, Kim H, Cho JY, et al. Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. Radiology. 2014;271:104–12.CrossRefPubMed
11.
Yu TY, Wang CY. Impact of non-alcoholic fatty pancreas disease on glucose metabolism. J Diabetes Investig. 2017. https://​doi.​org/​10.​1111/​jdi.​12665.
12.
Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter-2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig. 2015;6:587–90.CrossRefPubMedPubMedCentral

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Image Credits